Latest news with #EVH
Yahoo
28-05-2025
- Entertainment
- Yahoo
Rocker Pays ‘Awesome' Tribute to His Late Legendary Father by Playing His Iconic Guitar
Wolfgang Van Halen continues to pay tribute to guitar legend Eddie Van Halen by occasionally playing his father's guitar. On Monday, May 5, Wolfgang shared a video on X, formerly Twitter, of him playing his father's famed guitar known as Frankenstein, because the elder Van Halen customized the instrument by adding parts from various guitars. 🎬 SIGN UP for Parade's Daily newsletter to get the latest pop culture news & celebrity interviews delivered right to your inbox 🎬 In the 20-second clip, Wolfgang is seen playing along to a recorded track as he sits cross-legged. Fans will recognize the red guitar with the customized white and black stripes that became an Eddie Van Halen trademark. 'Fun fact, I recorded the main tapping of the song, and the slap part with the Frankenstein! Makes me feel closer to Pop that such an important part of his history can live with mine every time I record ❤️,' Wolfgang, who is the son of Valerie Bertinelli, captioned the clip. Fans were quick to comment on the clip. 'What an awesome nod to "Mean Streets" but in his own way. I wonder why no other guitarists have incorporated this technique. Maybe it was too hard, or maybe it sounded too much like EVH. Either way, this is awesome,' wrote one. Wolf replied to that comment by writing, 'Hah it's actually not, it's just a slap bass part on a guitar, but thank you!' 'So rad! How awesome to see that not only you are getting to make that connection, but we as fans get to continue to make a connection to EVH through you. The new song is just awesome! Great job Wolfie!' wrote another fan.
Washington Post
08-05-2025
- Business
- Washington Post
Evolent Health: Q1 Earnings Snapshot
ARLINGTON, Va. — ARLINGTON, Va. — Evolent Health Inc. (EVH) on Thursday reported a loss of $64.6 million in its first quarter. On a per-share basis, the Arlington, Virginia-based company said it had a loss of 63 cents. Earnings, adjusted for non-recurring costs and stock option expense, came to 6 cents per share.
Yahoo
05-05-2025
- Business
- Yahoo
1 Unprofitable Stock Worth Investigating and 2 to Question
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. Unprofitable companies face an uphill battle, but not all are created equal. Luckily for you, StockStory is here to separate the promising ones from the weak. Keeping that in mind, here is one unprofitable company that could turn today's losses into long-term gains and two that could struggle to survive. Trailing 12-Month GAAP Operating Margin: -33.1% Founded by a former CEO and Harvard-educated entrepreneur Scott Keeneyn, nLIGHT (NASDAQ:LASR) offers semiconductor and fiber lasers to the industrial, aerospace & defense, and medical sectors. Why Do We Avoid LASR? Annual sales declines of 9.4% for the past two years show its products and services struggled to connect with the market during this cycle Cash-burning tendencies make us wonder if it can sustainably generate shareholder value Eroding returns on capital from an already low base indicate that management's recent investments are destroying value nLIGHT is trading at $8.80 per share, or 2x forward price-to-sales. Read our free research report to see why you should think twice about including LASR in your portfolio, it's free. Trailing 12-Month GAAP Operating Margin: -1.6% Founded in 2011 to transform how healthcare is delivered to patients with complex needs, Evolent Health (NYSE:EVH) provides specialty care management services and technology solutions that help health plans and providers deliver better care for patients with complex conditions. Why Does EVH Worry Us? Sales are projected to tank by 18.9% over the next 12 months as demand evaporates Ability to fund investments or reward shareholders with increased buybacks or dividends is restricted by its weak free cash flow margin of 0.3% for the last five years Negative returns on capital show that some of its growth strategies have backfired Evolent Health's stock price of $10.50 implies a valuation ratio of 16.3x forward P/E. Check out our free in-depth research report to learn more about why EVH doesn't pass our bar. Trailing 12-Month GAAP Operating Margin: -1.3% Founded by Caltech professor Carver Mead and one of his students Chris Diorio, Impinj (NASDAQ:PI) is a maker of radio-frequency identification (RFID) hardware and software. Why Is PI on Our Radar? Annual revenue growth of 11.9% over the last two years was superb and indicates its market share increased during this cycle Performance over the past five years shows its incremental sales were extremely profitable, as its annual earnings per share growth of 48.4% outpaced its revenue gains Free cash flow margin increased by 23.7 percentage points over the last five years, giving the company more capital to invest or return to shareholders At $102 per share, Impinj trades at 61.7x forward P/E. Is now a good time to buy? Find out in our full research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like United Rentals (+322% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
Yahoo
10-04-2025
- Business
- Yahoo
1 Growth Stock to Stash and 2 to Keep Off Your Radar
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market's punishment can be swift and severe when trajectories fall. Deciphering which businesses can sustain their high growth rates is a challenge for even the most seasoned professionals, which is why we started StockStory. On that note, here is one growth stock with significant upside potential and two that could be down big. One-Year Revenue Growth: +16.4% Founded by Stanford University students Evan Spiegel, Reggie Brown, and Bobby Murphy, and originally called Picaboo, Snapchat (NYSE: SNAP) is an image centric social media network. Why Are We Wary of SNAP? Decision to emphasize platform growth over monetization has contributed to 2.5% annual declines in its average revenue per user Expenses have increased as a percentage of revenue over the last few years as its EBITDA margin fell by 5.5 percentage points Incremental sales over the last three years were much less profitable as its earnings per share fell by 14.7% annually while its revenue grew At $8.50 per share, Snap trades at 20.4x forward EV-to-EBITDA. Dive into our free research report to see why there are better opportunities than SNAP. One-Year Revenue Growth: +30.1% Founded in 2011 to transform how healthcare is delivered to patients with complex needs, Evolent Health (NYSE:EVH) provides specialty care management services and technology solutions that help health plans and providers deliver better care for patients with complex conditions. Why Are We Cautious About EVH? Projected sales decline of 18.9% for the next 12 months points to a tough demand environment ahead Poor free cash flow margin of 0.3% for the last five years limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends Negative returns on capital show management lost money while trying to expand the business Evolent Health is trading at $9.50 per share, or 15.3x forward price-to-earnings. If you're considering EVH for your portfolio, see our FREE research report to learn more. One-Year Revenue Growth: +19.8% Founded in Austria in 2005, Dynatrace (NYSE:DT) provides companies with software that allows them to monitor the performance of their full technology stack, from software applications to the infrastructure they run on. Why Are We Fans of DT? ARR trends over the last year show it's maintaining a steady flow of long-term contracts that contribute positively to its revenue predictability Prominent and differentiated software culminates in a premier gross margin of 82.2% Robust free cash flow margin of 24.9% gives it many options for capital deployment Dynatrace's stock price of $44 implies a valuation ratio of 7.3x forward price-to-sales. Is now a good time to buy? Find out in our full research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like United Rentals (+322% five-year return). Find your next big winner with StockStory today for free.
Globe and Mail
07-03-2025
- Business
- Globe and Mail
3 Reasons to Sell EVH and 1 Stock to Buy Instead
Evolent Health has gotten torched over the last six months - since September 2024, its stock price has dropped 71.1% to $8.76 per share. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation. Is now the time to buy Evolent Health, or should you be careful about including it in your portfolio? Get the full stock story straight from our expert analysts, it's free. Even though the stock has become cheaper, we're cautious about Evolent Health. Here are three reasons why you should be careful with EVH and a stock we'd rather own. Why Is Evolent Health Not Exciting? Founded in 2011, Evolent Health (NYSE:EVH) provides services to health systems (e.g. hospitals) and payers (e.g. insurance companies, government programs such as Medicare) focusing on improving care delivery and cost efficiency. 1. Revenue Projections Show Stormy Skies Ahead Forecasted revenues by Wall Street analysts signal a company's potential. Predictions may not always be accurate, but accelerating growth typically boosts valuation multiples and stock prices while slowing growth does the opposite. Over the next 12 months, sell-side analysts expect Evolent Health's revenue to drop by 18.9%, a decrease from its 37.5% annualized growth for the past two years. This projection is underwhelming and suggests its products and services will see some demand headwinds. 2. Breakeven Free Cash Flow Limits Reinvestment Potential Free cash flow isn't a prominently featured metric in company financials and earnings releases, but we think it's telling because it accounts for all operating and capital expenses, making it tough to manipulate. Cash is king. Evolent Health broke even from a free cash flow perspective over the last five years, giving the company limited opportunities to return capital to shareholders. 3. Previous Growth Initiatives Have Lost Money Growth gives us insight into a company's long-term potential, but how capital-efficient was that growth? A company's ROIC explains this by showing how much operating profit it makes compared to the money it has raised (debt and equity). Evolent Health's five-year average ROIC was negative 8.4%, meaning management lost money while trying to expand the business. Its returns were among the worst in the healthcare sector. Final Judgment Evolent Health isn't a terrible business, but it isn't one of our picks. After the recent drawdown, the stock trades at 14.2× forward price-to-earnings (or $8.76 per share). This valuation multiple is fair, but we don't have much faith in the company. We're pretty confident there are superior stocks to buy right now. Let us point you toward our favorite semiconductor picks and shovels play. Stocks We Like More Than Evolent Health With rates dropping, inflation stabilizing, and the elections in the rearview mirror, all signs point to the start of a new bull run - and we're laser-focused on finding the best stocks for this upcoming cycle. Put yourself in the driver's seat by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Comfort Systems (+751% five-year return). Find your next big winner with StockStory today for free.
